Bolt Biotherapeutics (BOLT) Operating Margin (2020 - 2025)
Historic Operating Margin for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to 355.14%.
- Bolt Biotherapeutics' Operating Margin rose 10859600.0% to 355.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 884.39%, marking a year-over-year decrease of 1082600.0%. This contributed to the annual value of 949.91% for FY2024, which is 175400.0% up from last year.
- According to the latest figures from Q3 2025, Bolt Biotherapeutics' Operating Margin is 355.14%, which was up 10859600.0% from 510.53% recorded in Q2 2025.
- Bolt Biotherapeutics' Operating Margin's 5-year high stood at 324.08% during Q1 2024, with a 5-year trough of 5329.72% in Q4 2021.
- Its 5-year average for Operating Margin is 1565.75%, with a median of 1221.0% in 2022.
- Per our database at Business Quant, Bolt Biotherapeutics' Operating Margin surged by 38385800bps in 2022 and then tumbled by -7218400bps in 2024.
- Over the past 5 years, Bolt Biotherapeutics' Operating Margin (Quarter) stood at 5329.72% in 2021, then surged by 72bps to 1491.14% in 2022, then skyrocketed by 37bps to 946.19% in 2023, then tumbled by -52bps to 1441.1% in 2024, then soared by 75bps to 355.14% in 2025.
- Its Operating Margin stands at 355.14% for Q3 2025, versus 510.53% for Q2 2025 and 991.41% for Q1 2025.